Children's Oncology Group's 2023 blueprint for research: Development therapeutics

被引：3
|
作者：
Fox, Elizabeth [1 ]
Parsons, D. Williams J. [2 ]
Weigel, Brenda [3 ,4 ]
Dev Therapeutics Comm
机构：
[1] St Jude Childrens Res Hosp, Memphis, TN USA
[2] Baylor Coll Med, Texas Childrens Canc & Hematol Ctr, Houston, TX USA
[3] Univ Minnesota, Div Pediat Hematol & Oncol, Med Ctr, Minneapolis, MN USA
[4] Univ Minnesota, Div Pediat Hematol & Oncol, Med Ctr, Mail Code 484,420 Delaware St SE, Minneapolis, MN 55455 USA
来源：
PEDIATRIC BLOOD & CANCER | 2023年 / 70卷
关键词：
phase; 2; precision medicine; trial design; PATHWAY; TRIAL;
D O I：
10.1002/pbc.30563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The Developmental Therapeutics Committee (DVL) identifies and develops new agents and treatment strategies for children/adolescents with cancer, through clinical and translational research. DVL has focused on evaluating the activity of targeted therapy and has evolved from trials with multiple histology strata to biomarker-selected phase 2 trials. These trials have included single-agent studies to evaluate agents such as cabozantinib in multi-disease cohorts, to trametinib, larotrectinib, and lorvotuzumab in disease-specific cohorts, as well as the pediatric Molecular Analysis for Therapy Choice (MATCH) study including multiple single agents targeted for biomarker-selected pediatric tumors. The ongoing vision and direction of DVL is to support the disease committees of COG to develop novel agents and combinations to advance the care of children with cancer.
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia
    Hunger, Stephen P.
    Loh, Mignon L.
    Whitlock, James A.
    Winick, Naomi J.
    Carroll, William L.
    Devidas, Meenakshi
    Raetz, Elizabeth A.
    PEDIATRIC BLOOD & CANCER, 2013, 60 (06) : 957 - 963
  • [42] Children's Oncology Group's 2013 blueprint for research: Central nervous system tumors
    Gajjar, Amar
    Packer, Roger J.
    Foreman, N. K.
    Cohen, Kenneth
    Haas-Kogan, Daphne
    Merchant, Thomas E.
    PEDIATRIC BLOOD & CANCER, 2013, 60 (06) : 1022 - 1026
  • [43] Children's Oncology Group's 2013 blueprint for research: Cancer control and supportive care
    Sung, Lillian
    Zaoutis, Theo
    Ullrich, Nicole J.
    Johnston, Donna
    Dupuis, Lee
    Ladas, Elena
    PEDIATRIC BLOOD & CANCER, 2013, 60 (06) : 1027 - 1030
  • [44] Children's Oncology Group's 2013 blueprint for research: Non-Hodgkin lymphoma
    Bollard, Catherine M.
    Lim, Megan S.
    Gross, Thomas G.
    PEDIATRIC BLOOD & CANCER, 2013, 60 (06) : 979 - 984
  • [45] Children's Oncology Group's 2013 blueprint for research: stem cell transplantation (vol 60, pg 1044, 2013)
    Grupp, S. A.
    Dvorak, C. C.
    Nieder, M. L.
    PEDIATRIC BLOOD & CANCER, 2017, 64 (02) : 397 - 397
  • [46] Children's Oncology Group's 2013 Blueprint for Research: Neuroblastoma. Pediatr Blood Cancer (vol 985, pg 60, 2013)
    Park, Julie R.
    Bagatell, Rochelle
    London, Wendy B.
    Maris, John M.
    Cohn, Susan L.
    Mattay, Katherine K.
    Hogarty, Michael
    PEDIATRIC BLOOD & CANCER, 2014, 61 (05) : 958 - 958
  • [47] Early phase drug development in the Children's Oncology Group
    Adamson, P. C.
    EJC SUPPLEMENTS, 2008, 6 (12): : 9 - 9
  • [48] The Children's Oncology Group epidemiology program: Opportunities for cancer research
    Ross, JA
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (11) : 1363S - 1363S
  • [49] Implementation of Recommentations for Return of Research Results in the Children's Oncology Group
    Ruccione, K.
    Pyke-Grimm, K.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S409 - S410
  • [50] Psychological research in childhood cancer: The children's oncology group perspective
    Armstrong, FD
    Reaman, GH
    JOURNAL OF PEDIATRIC PSYCHOLOGY, 2005, 30 (01) : 89 - 97
12345